Induction of CD4+CD25+ Regulatory T Cells by Copolymer-I Through Activation of Transcription Factor Foxp3

Overview

Journal Proc Natl Acad Sci U S A

Specialty Science

Date 2005 Apr 27

PMID 15851684

Citations 86

Authors

Jian Hong

Ningli Li

Xuejun Zhang

Biao Zheng

Jingwu Z Zhang

Affiliations

Soon will be listed here.

Abstract

Copolymer-I (COP-I) has unique immune regulatory properties and is a treatment option for multiple sclerosis (MS). This study revealed that COP-I induced the conversion of peripheral CD4+CD25- to CD4+CD25+ regulatory T cells through the activation of transcription factor Foxp3. COP-I treatment led to a significant increase in Foxp3 expression in CD4+ T cells in MS patients whose Foxp3 expression was reduced at baseline. CD4+CD25+ T cell lines generated by COP-I expressed high levels of Foxp3 that correlated with an increased regulatory potential. Furthermore, we demonstrated that the induction of Foxp3 in CD4+ T cells by COP-I was mediated through its ability to produce IFN-gamma and, to a lesser degree, TGF-beta1, as shown by antibody blocking and direct cytokine induction of Foxp3 expression in T cells. It was evident that in vitro treatment and administration with COP-I significantly raised the level of Foxp3 expression in CD4+ T cells and promoted conversion of CD4+CD25+ regulatory T cells in wild-type B6 mice but not in IFN-gamma knockout mice. This study provides evidence for the role and mechanism of action of COP-I in the induction of CD4+CD25+ regulatory T cells in general and its relevance to the treatment of MS.

Citing Articles

Cardioprotective effects of glatiramer acetate after ischemic myocardial injury.

Hofmann U, Frantz S Nat Cardiovasc Res. 2024; 3(9):1024-1025.

PMID: 39271813 DOI: 10.1038/s44161-024-00517-w.

Treatment with glatiramer acetate in APPswe/PS1dE9 mice at an early stage of Alzheimer's disease prior to amyloid-beta deposition delays the disease's pathological development and ameliorates cognitive decline.

Huang Z, Gong Z, Lin Y, Yang F, Chen W, Xiang S Front Aging Neurosci. 2024; 16:1267780.

PMID: 38352237 PMC: 10861656. DOI: 10.3389/fnagi.2024.1267780.

Repurposing MS immunotherapies for CIDP and other autoimmune neuropathies: unfulfilled promise or efficient strategy?.

Kohle F, Dalakas M, Lehmann H Ther Adv Neurol Disord. 2023; 16:17562864221137129.

PMID: 36620728 PMC: 9810996. DOI: 10.1177/17562864221137129.

Impact of disease-modifying therapy on dendritic cells and exploring their immunotherapeutic potential in multiple sclerosis.

Liu C, Zhu J, Mi Y, Jin T J Neuroinflammation. 2022; 19(1):298.

PMID: 36510261 PMC: 9743681. DOI: 10.1186/s12974-022-02663-z.

Multidimensional overview of neurofilament light chain contribution to comprehensively understanding multiple sclerosis.

Kolliker Frers R, Otero-Losada M, Kobiec T, Udovin L, Aon Bertolino M, Herrera M Front Immunol. 2022; 13:912005.

PMID: 35967312 PMC: 9368191. DOI: 10.3389/fimmu.2022.912005.

References

Moreau T, Coles A, Wing M, Isaacs J, Hale G, Waldmann H . Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis. Brain. 1996; 119 ( Pt 1):225-37. DOI: 10.1093/brain/119.1.225. View

Gran B, Tranquill L, Chen M, Bielekova B, Zhou W, Dhib-Jalbut S . Mechanisms of immunomodulation by glatiramer acetate. Neurology. 2000; 55(11):1704-14. DOI: 10.1212/wnl.55.11.1704. View

Waisman A, Ruiz P, Hirschberg D, Gelman A, Oksenberg J, Brocke S . Suppressive vaccination with DNA encoding a variable region gene of the T-cell receptor prevents autoimmune encephalomyelitis and activates Th2 immunity. Nat Med. 1996; 2(8):899-905. DOI: 10.1038/nm0896-899. View

Hong J, Zang Y, Hutton G, Rivera V, Zhang J . Gene expression profiling of relevant biomarkers for treatment evaluation in multiple sclerosis. J Neuroimmunol. 2004; 152(1-2):126-39. DOI: 10.1016/j.jneuroim.2004.03.004. View

Teitelbaum D, Milo R, Arnon R, Sela M . Synthetic copolymer 1 inhibits human T-cell lines specific for myelin basic protein. Proc Natl Acad Sci U S A. 1992; 89(1):137-41. PMC: 48191. DOI: 10.1073/pnas.89.1.137. View

Racke M, Martin R, McFarland H, Fritz R . Copolymer-1-induced inhibition of antigen-specific T cell activation: interference with antigen presentation. J Neuroimmunol. 1992; 37(1-2):75-84. DOI: 10.1016/0165-5728(92)90157-g. View

Barth H, Klein K, Bortlein A, Guseo A, Berg P, Wietholter H . Analysis of immunoregulatory T-helper cell subsets in patients with multiple sclerosis: relapsing-progressive course correlates with enhanced T H1, relapsing-remitting course with enhanced T H0 reactivity. J Neuroimmunol. 2002; 133(1-2):175-83. DOI: 10.1016/s0165-5728(02)00355-7. View

Fridkis-Hareli M, Teitelbaum D, Gurevich E, Pecht I, Brautbar C, Kwon O . Direct binding of myelin basic protein and synthetic copolymer 1 to class II major histocompatibility complex molecules on living antigen-presenting cells--specificity and promiscuity. Proc Natl Acad Sci U S A. 1994; 91(11):4872-6. PMC: 43891. DOI: 10.1073/pnas.91.11.4872. View

Fantini M, Becker C, Monteleone G, Pallone F, Galle P, Neurath M . Cutting edge: TGF-beta induces a regulatory phenotype in CD4+CD25- T cells through Foxp3 induction and down-regulation of Smad7. J Immunol. 2004; 172(9):5149-53. DOI: 10.4049/jimmunol.172.9.5149. View

10.

Khattri R, Cox T, Yasayko S, Ramsdell F . An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nat Immunol. 2003; 4(4):337-42. DOI: 10.1038/ni909. View

11.

Lafaille J, Keere F, Hsu A, Baron J, Haas W, Raine C . Myelin basic protein-specific T helper 2 (Th2) cells cause experimental autoimmune encephalomyelitis in immunodeficient hosts rather than protect them from the disease. J Exp Med. 1997; 186(2):307-12. PMC: 2198987. DOI: 10.1084/jem.186.2.307. View

12.

Ziemssen T, Kumpfel T, Klinkert W, Neuhaus O, Hohlfeld R . Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain-derived neurotrophic factor. Brain. 2002; 125(Pt 11):2381-91. DOI: 10.1093/brain/awf252. View

13.

Bornstein M, Miller A, SLAGLE S, Weitzman M, Crystal H, DREXLER E . A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis. N Engl J Med. 1987; 317(7):408-14. DOI: 10.1056/NEJM198708133170703. View

14.

Dhib-Jalbut S, Chen M, Said A, Zhan M, Johnson K, Martin R . Glatiramer acetate-reactive peripheral blood mononuclear cells respond to multiple myelin antigens with a Th2-biased phenotype. J Neuroimmunol. 2003; 140(1-2):163-71. DOI: 10.1016/s0165-5728(03)00170-x. View

15.

Miller A, Shapiro S, Gershtein R, Kinarty A, Rawashdeh H, Honigman S . Treatment of multiple sclerosis with copolymer-1 (Copaxone): implicating mechanisms of Th1 to Th2/Th3 immune-deviation. J Neuroimmunol. 1999; 92(1-2):113-21. DOI: 10.1016/s0165-5728(98)00191-x. View

16.

Fontenot J, Gavin M, Rudensky A . Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol. 2003; 4(4):330-6. DOI: 10.1038/ni904. View

17.

Zhang J, Hutton G . Role of magnetic resonance imaging and immunotherapy in treating multiple sclerosis. Annu Rev Med. 2005; 56:273-302. DOI: 10.1146/annurev.med.56.082103.104739. View

18.

Kukreja A, Cost G, Marker J, Zhang C, Sun Z, Lin-Su K . Multiple immuno-regulatory defects in type-1 diabetes. J Clin Invest. 2002; 109(1):131-40. PMC: 150819. DOI: 10.1172/JCI13605. View

19.

Walker M, Kasprowicz D, Gersuk V, Benard A, Van Landeghen M, Buckner J . Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+CD25- T cells. J Clin Invest. 2003; 112(9):1437-43. PMC: 228469. DOI: 10.1172/JCI19441. View

20.

Brunkow M, Jeffery E, Hjerrild K, Paeper B, Clark L, Yasayko S . Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat Genet. 2001; 27(1):68-73. DOI: 10.1038/83784. View